New injection targets double chin: embella tested in small trial
NCT ID NCT06509438
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed study tested the safety and effectiveness of Embella (deoxycholic acid) injections for reducing submental fat, also known as a double chin. Twenty adults aged 18 to 65 with unwanted chin fat received injections and were followed for 3 months. The goal was to see if the treatment could improve fat grading and reduce fat thickness.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Deoxycholic acid (injectable solution, brand name Embella)
- What this could lead to
- If it works, this could offer a non-surgical option to reduce chin fat and improve appearance.
- What could go wrong
- This is a small, completed trial with only 20 participants. Results may not apply to everyone, and side effects like pain or swelling are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Apr 2023
- Finished
-
Jan 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age between 18 and 65 years. * Individuals with unwanted submental fat of any severity. * Ability to comply with visit schedules and study procedures. * Signed informed consent form and agreement to a 3-month follow-up. Exclusion Criteria: * Any previous intervention for the treatment of submental fat (SMF). * Specific anatomical features or previous damage to the intervention site (e.g., scars, liposuction, swallowing difficulties, enlarged thyroid or lymph nodes) that could interfere with the assessment of intervention outcomes. * Evidence of submental enlargement due to reasons other than SMF. * History of dysphagia. * Body mass index (BMI) \> 30 kg/m². * Individuals currently on a weight loss program. * History of allergy to any components of the drug or local anesthetics. * Presence of any inflammation, active infection, unhealed wounds, or skin lesions in the injection area. * Use of any anticoagulants, NSAIDs, or any other medications that increase the risk of coagulation disorders within 7 days before injection. * Unrealistic expectations. * Pregnant or breastfeeding women. * Individuals on sodium-restricted diets, such as those with uncontrolled hypertension.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Submental fullness are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Center for Research and Training in Skin Diseases and Leprosy
Tehran, 1416613675, Iran
More trials for these conditions
Other studies related to the condition(s) this trial covers.